Understanding the Genetic
Architecture of Parkinson's Disease
The Global Parkinson’s Genetics Program (GP2) is an ambitious five-year program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease (PD). There is still much to learn about genetic risk factors and the path to further understanding requires working collaboratively and openly sharing data, processes, and results.
Recruiting and investigating Parkinson’s disease patients with a potential monogenic basis.
Submit a Cohort
Collaborate with us and submit a cohort to GP2. Fill out our form to get started.
Check out the latest news about GP2.
First-of-its-Kind DNA Biobank Opens in Peru
ASAP, through GP2 and in partnership with LARGE-PD and the MJFF, celebrated a shared milestone with the inauguration of the DNA Biobank at the Instituto Nacional de Ciencias Neurológicas. The Biobank will help accelerate collaboration and greater genetic representation of Latin American participants in research.
Latest Blog Posts
Read the latest blogs from GP2’s scientists and collaborators.
Understanding GWAS: Part 2 – Additional Insights and Tips
As a follow-up to the last blog post on Understanding GWAS, the GP2 Complex Disease Data Analysis Working Group has provided practical tips and insights for running your own GWAS.
GP2 and AMP PD: Platform Partners for Progress in Parkinson’s Research
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post.
What is Compliance and Why is it Important?
Members of the GP2 Operations and Compliance working group provide an overview of what compliance is and why it is important in GP2.
Find out about GP2’s working groups and their recently accomplished milestones.